Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort

Eur J Gastroenterol Hepatol. 2010 Feb;22(2):157-66. doi: 10.1097/MEG.0b013e328330a8e8.

Abstract

Objectives: To analyze the data (epidemiology, mode of transmission, course, and outcome) of a large series of patients with acute hepatitis C (AHC) in France.

Methods: Prospective multicenter register, observational study.

Results: A cohort of 126 patients with AHC was prospectively enrolled between 1999 and 2007. Fifteen (12%) were HIV coinfected. Suspected modes of hepatitis C virus transmission were drug use (38%), sexual contact (21%), nosocomial transmission (18%), and occupational exposure (12%). For 40% of the patients, AHC was revealed by jaundice. Spontaneous viral clearance occurred in 40% of the 72 patients observed for 3 months without treatment. Only jaundice and nosocomial/occupational transmission were predictive of spontaneous viral clearance. Ninety patients were treated with standard or pegylated interferon-alpha alone (58%) or in combination with ribavirin (42%), for 24 weeks or less in 90%. In intention-to-treat, a sustained viral response was obtained in 58 of 78 (74%) hepatitis C virus monoinfected patients [19 of 22 (86%) with 24 weeks of pegylated interferon-alpha alone], but only six of 12 (50%) of HIV coinfected patients.

Conclusion: AHC remains rare, and drug and sexual transmission are predominant. A 3-month follow-up after diagnosis avoids treatment for four out of 10 patients. Antiviral treatment is highly effective, 24 weeks of pegylated interferon-alpha alone being a good option.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • Belgium / epidemiology
  • Drug Therapy, Combination
  • Female
  • France / epidemiology
  • HIV Infections / epidemiology
  • Hepacivirus / genetics
  • Hepatitis C* / diagnosis
  • Hepatitis C* / drug therapy
  • Hepatitis C* / epidemiology
  • Hepatitis C* / transmission
  • Humans
  • Interferon Type I / therapeutic use
  • Luxembourg / epidemiology
  • Male
  • Middle Aged
  • Prospective Studies
  • RNA, Viral / blood
  • Recombinant Proteins
  • Registries
  • Remission, Spontaneous
  • Ribavirin / therapeutic use
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Viral Load
  • Young Adult

Substances

  • Antiviral Agents
  • Interferon Type I
  • RNA, Viral
  • Recombinant Proteins
  • Ribavirin